Efficacy, safety of combined perindopril and indapamide low-dose therapy in patients with arterial hypertension and metabolic syndrome

Abstract

Aim. To study clinical, hemodynamic, and metabolic effects of 12-week therapy with Noliprel® (perindopril 2 mg plus indapamide 0.625 mg) in patients with arterial hypertension (AH) and metabolic syndrome (MS). Material and methods. Twenty-five patients with AH and MS were enrolled in the study. At baseline, as well as after 12 weeks of Noliprel® and Noliprel Forte® therapy, 24-hour blood pressure monitoring (BPM), metabolic and hemostatic parameters’ assessments were performed. Results. Twelve-week therapy with Noliprel® and Noliprel Forte® resulted in decrease of circadian BP, day- and night-time pressure load indices, and BP bi-phase profile normalization. Treatment with Noliprel® and Noliprel Forte® did not significantly influence plasma levels of lipids, glucose, or insulin. Initially increased platelet aggregation substantially improved during the treatment. Conclusion. The results obtained demonstrate good antihypertensive effects during the whole day, and metabolic neutrality for both medications.

Keywords

• метаболический синдром
• низкодозовая комбинированная терапия
• артериальная гипертония
• агрегация тромбоцитов
• метаболическая нейтральность